Benefits of Nonionic Contrast in Coronary Arteriography Preliminary Results of a Randomized Double-Blind Trial Comparing Iopamidol with Renografin-76

Publisher Website
Google Scholar
Abstract
The cardiovascular effects of the commonly used ionic contrast, 76% sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4% versus 13%) P < 0.001, heart rate (4% versus 26%) P < 0.01, and left ventricular contractility, P < 0.03, than Renografun-76. In addition, intracoronary iopamidol prolonged the QT interval less (23% versus 2%) P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60% versus 153%) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.

This publication has 0 references indexed in Scilit: